Background: Evaluation of the time from HIV diagnosis to viral suppression (VS) captures the collective effectiveness of HIV prevention and treatment activities in a given locale and provides a more global estimate of how effectively the larger HIV care system is working in a given geographic area or jurisdiction.
Objective: This study aimed to evaluate temporal and geographic variability in VS among persons with newly diagnosed HIV infection in Alabama between 2012 and 2014.
Methods: With data from the National HIV Surveillance System, we evaluated median time from HIV diagnosis to VS (<200 c/mL) overall and stratified by Alabama public health area (PHA) among persons with HIV diagnosed during 2012 to 2014 using the Kaplan-Meier approach.
Results: Among 1979 newly diagnosed persons, 1181 (59.67%) achieved VS within 12 months of diagnosis; 52.6% (353/671) in 2012, 59.5% (377/634) in 2013, and 66.9% (451/674) in 2014. Median time from HIV diagnosis to VS was 8 months: 10 months in 2012, 8 months in 2013, and 6 months in 2014. Across 11 PHAs in Alabama, 12-month VS ranged from 45.8% (130/284) to 84% (26/31), and median time from diagnosis to VS ranged from 5 to 13 months.
Conclusions: Temporal improvement in persons achieving VS following HIV diagnosis statewide in Alabama is encouraging. However, considerable geographic variability warrants further evaluation to inform public health action. Time from HIV diagnosis to VS represents a meaningful indicator that can be incorporated into public health surveillance and programming.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275256 | PMC |
| http://dx.doi.org/10.2196/17217 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Effectiveness and Tolerability of Dolutegravir and Lamivudine 2-Drug Regimen in People Living with HIV: Systematic Literature Review and Meta-Analysis.
Infect Dis Ther
January 2025
ViiV Healthcare, Madrid, Spain.
Introduction: Dolutegravir (DTG) + lamivudine (3TC) demonstrated high rates of virologic suppression (VS) and low rates of virologic failure (VF), discontinuation, and drug resistance in randomized trials. Real-world evidence can support treatment effectiveness, safety, and tolerability in clinical practice and aid in treatment decisions.
Methods: A systematic literature review (SLR) was conducted to identify studies using DTG + 3TC (January 2013-March 2024).
A blueprint for large language model-augmented telehealth for HIV mitigation in Indonesia: A scoping review of a novel therapeutic modality.
Health Informatics J
January 2025
Department of Computer Science and Information Technology, La Trobe University, Melbourne, VIC, Australia.
The HIV epidemic in Indonesia is one of the fastest growing in Southeast Asia and is characterised by a number of geographic and sociocultural challenges. Can large language models (LLMs) be integrated with telehealth (TH) to address cost and quality of care? A literature review was performed using the PRISMA-ScR (2018) guidelines between Jan 2017 and June 2024 using the PubMed, ArXiv and semantic scholar databases. Of the 694 records identified, 12 studies met the inclusion criteria.
View Article and Find Full Text PDFClinical events associated with poor CD4 T-cell recovery in people living with HIV following ART: a systematic review and meta-analysis.
J Infect
January 2025
Research Center for Clinical Medicine, First Affiliated Hospital of Kunming Medical University, Kunming 650032, China; Department of Science and Research, The Affiliated Anning First People's Hospital of Kunming University of Science and Technology, Kunming 650300, China; Yunnan Key Laboratory of Stem Cell and Regenerative Medicine, Kunming Medical University, Kunming 650500, China; School of Basic Medical Sciences, Kunming University of Science and Technology, Kunming 650500, China. Electronic address:
Background: Antiretroviral therapy (ART) has significantly improved outcomes for people living with HIV (PLWH), but poor CD4 T-cell recovery remains a challenge. This study aimed to evaluate the relationship between poor CD4 T-cell recovery and the morbidity of clinical events (CEs) in PLWH after ART initiation.
Methods: We conducted a comprehensive search of the EMBASE, PubMed, Web of Science, and Cochrane Library databases up to February 19, 2024, and included studies that reported the number of CEs along with the CD4 count at the time of the CEs or the most recent CD4 count prior to the CEs.
Retrospective analysis of CD4 count trends in South Africa.
South Afr J HIV Med
December 2024
Wits Diagnostic Innovation Hub, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Background: South Africa has the largest HIV epidemic globally. Despite the scale-up of antiretroviral therapy, people living with HIV are still presenting with low CD4 counts.
Objectives: This study assessed CD4 trends.
MicroRNA in neuroexosome as a potential biomarker for HIV-associated neurocognitive disorders.
J Neurovirol
January 2025
Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-Ku, Tokyo, 108-8639, Japan.
HIV-associated neurocognitive disorder (HAND) is a complication of chronic inflammation caused by HIV infection that impairs cognitive and motor functions. HAND can occur at any age, regardless of the duration of infection, even in people living with HIV (PLWH) whose blood viral load is controlled by antiretroviral therapy. The diagnosis of HAND requires a battery of neuropsychological tests, which is time-consuming and burdensome, limiting its effectiveness for screening PLWH.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!